{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+60+MG&page=2", "query": { "intervention": "Selinexor 60 MG", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+60+MG&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+60+MG&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T04:25:21.609Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02628704", "title": "Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Placebo (for selinexor)", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 2, "location_summary": "West Hollywood, California • Cary, North Carolina", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Cary", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628704" }, { "nct_id": "NCT04782687", "title": "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Myeloma Multiple", "Kahler Disease", "Myeloma, Plasma Cell", "Myeloma-Multiple", "Myelomatosis", "Plasma Cell Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2021-09-10", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 10, "location_summary": "Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Albany", "state": "New York" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04782687" }, { "nct_id": "NCT05983276", "title": "Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-16", "completion_date": "2031-08-28", "has_results": false, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05983276" }, { "nct_id": "NCT04607772", "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-11-18", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 18, "location_summary": "Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607772" }, { "nct_id": "NCT04216329", "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliosarcoma", "Newly Diagnosed", "Glioblastoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Generic Radiation therapy (RT)", "type": "RADIATION" }, { "name": "Selective serotonin receptor (5-HT3) antagonists", "type": "OTHER" }, { "name": "Olanzapine", "type": "OTHER" }, { "name": "Salt tablets", "type": "DIETARY_SUPPLEMENT" }, { "name": "Anti-diarrheal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-07-07", "completion_date": "2028-07-30", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216329" }, { "nct_id": "NCT04843579", "title": "Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma Multiple", "Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 4, "start_date": "2021-12-29", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 2, "location_summary": "Brooklyn, New York • New York, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843579" }, { "nct_id": "NCT03880123", "title": "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liposarcoma", "Malignant Peripheral Nerve Sheath Tumors", "Alveolar Soft Part Sarcoma", "Ewing Sarcoma", "Sarcoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Ingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 0, "start_date": "2020-11", "completion_date": "2020-11-24", "has_results": false, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03880123" }, { "nct_id": "NCT02403310", "title": "A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Acute Myeloid Leukemia", "AML" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-06-18", "completion_date": "2021-02-01", "has_results": false, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02403310" }, { "nct_id": "NCT02402764", "title": "Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-07-08", "completion_date": "2019-06-06", "has_results": true, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02402764" }, { "nct_id": "NCT02343042", "title": "Selinexor and Backbone Treatments of Multiple Myeloma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2015-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-06T04:25:21.609Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343042" } ] }